We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
126
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$945K 0.06%
23,444
+8,986
+62% +$382K
TLPH icon
127
Talphera
TLPH
$67.5M
$903K 0.06%
3,992
-3,412
-46% -$593K
ZGNX
128
DELISTED
Zogenix, Inc.
ZGNX
$882K 0.06%
+32,063
New +$719K
OXGN
129
DELISTED
OXIGENE INC COM
OXGN
$871K 0.06%
+345,658
New +$929K
INVA icon
130
CALL
Innoviva
INVA
$1.61B
$809K 0.05%
282
-440
-61% -$12.9K
OCRX
131
DELISTED
Ocera Therapeutics, Inc.
OCRX
$779K 0.05%
+59,984
New +$560K
PCYC
132
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$772K 0.05%
73
-82
-53% -$9.95K
KERX
133
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$767K 0.05%
592
-1,689
-74% -$20.2K
IDIX
134
CALL
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$761K 0.05%
+1,273
New +$5.89K
SGYPW
135
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$751K 0.05%
+349,217
New +$575K
RXII
136
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
$709K 0.05%
+1,430
New +$709K
INFI
137
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$702K 0.04%
508
– –
HSTO
138
DELISTED
Histogen Inc. Common Stock
HSTO
$683K 0.04%
529
+71
+16% +$113K
NWBO
139
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$683K 0.04%
+1,812
New +$7.01K
VIRX
140
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$672K 0.04%
+7
New +$7.24K
GEVO icon
141
Gevo
GEVO
$363M
$663K 0.04%
+77
New +$737K
AMBI
142
DELISTED
Ambit Biosciences Corp
AMBI
$627K 0.04%
+65,000
New +$868K
BCRX icon
143
PUT
BioCryst Pharmaceuticals
BCRX
$2.48B
$602K 0.04%
+792
New +$5.01K
ECYT
144
DELISTED
Endocyte, Inc. Common Stock
ECYT
$597K 0.04%
+55,849
New +$617K
AMRN
145
CALL
Amarin Corp
AMRN
$293M
$588K 0.04%
149
-429
-74% -$22.2K
TLPH icon
146
CALL
Talphera
TLPH
$67.5M
$580K 0.04%
26
+16
+160% +$2.78K
AVNR
147
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$559K 0.04%
+1,663
New +$6.87K
VIRX
148
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$530K 0.03%
+533
New +$551K
IONS icon
149
Ionis Pharmaceuticals
IONS
$9.14B
$524K 0.03%
13,157
+1,494
+13% +$53.2K
IONS icon
150
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$518K 0.03%
130
– –
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.